Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9338341 | 0.79 | L3MBTL1 (0.56) | KDM4ECYP1A2ADRB2ADRB1TSHR | |
| SCHEMBL7249906 | 0.76 | PPARA (0.56) | — | |
| SCHEMBL4756301 | 0.75 | PPARG (0.41) | LMNASMN1; SMN2HSD17B10MAPTL3MBTL1 | |
| SCHEMBL7069421 | 0.75 | SIRT2 (0.43) | KDM4ELMNASMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL27541825 | 0.74 | PPARA (0.50) | LMNASMN1; SMN2MAPTL3MBTL1HTR1A | |
| SCHEMBL1247116 | 0.74 | ADRB2 (0.45) | ADRB2ADRB1MAPTNPSR1L3MBTL1 | |
| SCHEMBL3372793 | 0.71 | APP (0.42) | — | |
| SCHEMBL5095387 | 0.71 | APP (0.42) | — | |
| SCHEMBL9119398 | 0.71 | CYP4F2 (0.45) | CYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL27424457 | 0.71 | CHEK1 (0.38) | KDM4ELMNACYP1A2SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC. | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CYP11B1, CYP46A1, CYP51A1 | KDM4E 2843/4885LMNA 1390/4885CYP1A2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.